Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”

키워드

참고문헌 (17)

1. Goossens N, "Hepatitis C virus-induced hepatocel-lular carcinoma", Clin Mol Hepatol, 21, pp.105~114 (2015)
2. Na SK, "Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C", Clin Mol Hepatol, 25, pp.234~244 (2019)
3. Parikh ND, "Barriers to surveillance for hepatocellular carcinoma in a multicenter cohort", JAMA Netw Open, 5, pp.e2223504~ (2022)
4. Tzartzeva K, "Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis : A meta-analysis", Gastroenterology, 154, pp.1706~1718 (2018)
5. Principles and practice of screening for disease, "Wilson JMG", WHO, ~, pp.Public Health Papers No 24 (1968)
6. Kanwal F, "Surveillance for hepatocellular carcinoma : Current best practice and future direction", Gastroenterology, 157, pp.54~64 (2019)
7. Singal AG, "Doylestown plus and GALAD demonstrate high sensitivity for HCC detection in patients with cirrhosis", Clin Gastroenterol Hepatol, 20, pp.953~955 (2022)
8. Chalasani NP, "Validation of a novel multitarget blood test shows high sensitivity to detect early stage hepatocellular carcinoma", Clin Gastroenterol Hepatol, 20, pp.173~182 (2022)
9. Taggart D, "LBO-006 A prospective, blinded, multicenter U.S. evaluation of a multianalyte blood-based test for the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis", J Hepatol, 80(Suppl 1), pp.S11~ (2024)
10. Ioannou GN, "Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C", J Hepatol, 69, pp.1088~1098 (2018)
11. Fan R, "aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis", J Hepatol, 73, pp.1368~1378 (2020)
12. Tsai PC, "Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy", Clin Mol Hepatol, 30, pp.468~486 (2024)
13. Kwo PY, "Metformin and statins and their role in reducing hepatocellular carcinoma risk : Randomized trials are needed : Editorial on"Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy"", Clin Mol Hepatol, 30, pp.714~717 (2024)
14. Huang CF, "Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era : Correspondence to editorial on"Unmet needs in the post-direct-acting antivirals era : The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication"", Clin Mol Hepatol, 30, pp.1023~1025 (2024)
15. Simon TG, "Lifestyle and environmental approaches for the primary prevention of hepatocellular carcinoma", Clin Liver Dis, 24, pp.549~576 (2020)
16. Nishida N, "Metabolic disease as a risk of hepatocellular carcinoma", Clin Mol Hepatol, 27, pp.87~90 (2021)
17. Taniai M, "Alcohol and hepatocarcinogenesis", Clin Mol Hepatol, 26, pp.736~741 (2020)

관련 논문AI추천